Journal · GLP-1 & Metabolic Health
GLP-1 medicines have become the most talked-about drugs of the decade. In 2026 the story moved on again: tablets arrived, doses went up, and the number of people losing significant weight kept climbing. For aesthetic practitioners, that is not a side note. It is one of the biggest forces reshaping who walks into a clinic and what they need.
GLP-1 (glucagon-like peptide-1) is a gut hormone that helps regulate blood sugar, slows stomach emptying and signals fullness to the brain. Medicines that mimic it, such as semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro), lead to substantial weight loss in many patients. They are prescription-only medicines and must be prescribed after a proper clinical assessment.
The most visible change was the arrival of oral options for weight management in the UK. An oral form of semaglutide for weight loss was reported to have received MHRA authorisation in June 2026, and in August 2026 the MHRA was reported to have approved orforglipron, marketed as Foundayo, a once-daily non-peptide GLP-1 tablet that does not need to be taken on an empty stomach. Tablets remove the barrier of injections for many patients, which is likely to widen use further.
Higher-dose injectable regimens became available, and the next generation, including triple agonists such as retatrutide and combinations such as CagriSema, continued through late-stage trials. Each step has pushed average weight loss higher.
Large outcome trials have linked GLP-1 therapy with fewer major cardiovascular events, and research continues into kidney disease, sleep apnoea, liver disease and more. That broadening is why longevity researchers increasingly discuss GLP-1s alongside other “healthspan” interventions. Read more in Will we live forever?
“Ozempic face” is a media term, not a diagnosis, but it describes something practitioners see daily. Rapid or significant weight loss reduces facial fat, particularly in the mid-face, temples and around the mouth. Combined with skin that may not retract fully, the result can be hollowing, laxity and a tired or older look, even as overall health improves.
Similar changes appear on the body, with skin laxity on the arms, abdomen and thighs.
GLP-1 patients are not asking to look thinner. They usually already are. They are asking to look like themselves again.
Practitioners should also take a careful medication history. Patients on GLP-1s may have changes in nutrition, hydration and protein intake that affect healing and recovery.
Build a post-weight-loss treatment protocol.
Every patient on a GLP-1 is a potential long-term aesthetic patient: motivated, health-conscious and going through visible change. Clinics that offer a joined-up pathway, from skin-quality support during weight loss to structural restoration afterwards, will earn loyalty that a single treatment never could.
No. The effect depends on how much and how quickly weight is lost, age, genetics and skin quality.
That is a clinical decision for your practitioner. Many recommend focusing on skin quality during active weight loss and planning volume restoration once weight is stable.
No. GLP-1 medicines are prescription-only and must be prescribed by a qualified prescriber after consultation. This article is for information only.
Sources: MHRA product authorisations and UK prescribing reports (2026); PrivateDoc UK coverage of Foundayo and oral semaglutide (2026); SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023). Always check the current SmPC for licensed indications.
Keep reading
Immortality is not on the horizon. But for the first time, therapies designed to slow or reverse parts of ageing are being tested in people. Here is what is real, what is hype and what it means for aesthetics.
In 2026 a therapy built on David Sinclair's epigenetic reprogramming research was given to people for the first time, in an attempt to restore sight lost to glaucoma and optic nerve stroke. Here is what the early data shows.
Regeneration over correction, GLP-1 pathways, licensing, longevity menus and AI consultations. The ten trends that will define aesthetic medicine in 2027.
